Ardelyx has crossed a threshold that few commercial-stage small-cap biotechs ever reach: with both approved tenapanor brands - IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for hyperphosphatemia in chronic kidney disease patients on dialysis - now generating durable, sequentially growing U.S. revenue, the platform has scaled. The latest product-sales print crossed the $100 million quarterly threshold, the company exited June with cash and short-term investments well in excess of long-term debt, and a posture that frames the central near-term debate.
The trade is no longer a binary bet on tenapanor reaching commercial scale. The new question is whether the company can translate the IBSRELA and XPHOZAH franchises into cash flow positivity while the Phase 3 ACCEL trial of tenapanor in chronic idiopathic constipation reads out in the second half of 2027 - a readout that, on the evidence of the latest filing, would more than double the addressable patient population for the IBS-C franchise. The bear case rests on the CCO transition disclosed in mid-August 2026, and on the structural Medicare reimbursement headwind that has been baked into the XPHOZAH franchise since the ESRD Prospective Payment System bundling in early 2025.
What the latest quarter really shows is that IBSRELA, not XPHOZAH, is the engine. The company is profitable on a product-level contribution basis, but reported a loss from operations because selling, general and administrative spend continues to outpace top-line growth. The market is pricing the gap between product-level economics and a still-loaded cost structure, and the Q2 print made that gap narrower without closing it.